Testing for dementia is not a single test but a layered process that typically starts with a short screening in your doctor’s office and, if needed, moves through blood work, brain imaging, and detailed cognitive evaluations. No one scan or quiz can confirm dementia on its own. A diagnosis comes from combining several types of evidence to identify cognitive decline, rule out treatable causes, and pinpoint the specific type of dementia involved.
What Happens at the First Appointment
The process usually begins when you or a family member raises concerns with a primary care doctor. The doctor will ask about the specific changes you’ve noticed, when they started, and how they’ve progressed. They’ll want to know about medications, alcohol use, mood changes, and family history of cognitive problems. This conversation matters more than people expect, because the pattern and timeline of symptoms help distinguish dementia from depression, medication side effects, and normal aging.
A neurological exam follows. The doctor checks balance, reflexes, sensory function, and movement to look for signs of conditions like stroke or Parkinson’s disease that could explain or contribute to cognitive symptoms. These physical findings also help differentiate between dementia types, since some forms affect movement early while others don’t.
Quick Cognitive Screening Tests
Most doctors use a brief, in-office screening tool as the first formal step. These aren’t diagnostic on their own but help determine whether further evaluation is warranted.
The Mini-Cog is one of the fastest options, taking only a few minutes. You’re asked to remember three words, draw a clock face showing a specific time, then recall those three words. Its sensitivity for detecting dementia ranges from 76% to 100%, meaning it catches most cases, though its specificity varies widely (27% to 85%), so a positive result doesn’t necessarily mean dementia is present.
The Montreal Cognitive Assessment (MoCA) is more thorough, covering memory, attention, language, and visual-spatial skills. A score below 26 out of 30 is the standard flag for possible mild cognitive impairment. At that cutoff, the MoCA catches at least 94% of people who have dementia, making it very good at not missing cases. The trade-off is that it also flags many people who turn out to be fine, with specificity of 60% or lower.
The Mini-Mental State Examination (MMSE) was once the go-to screening tool but is less reliable. Its sensitivity for detecting all-cause dementia ranges from just 23% to 76%, meaning it can miss a significant number of cases. It remains in use, but many clinicians now prefer the MoCA or Mini-Cog.
These screenings are starting points. A low score prompts more testing. A normal score in someone with clear real-world cognitive changes still warrants further evaluation, since no screening tool is perfect.
Blood Tests to Rule Out Treatable Causes
Before assuming symptoms are caused by a neurodegenerative disease, doctors order lab work to check for reversible conditions that mimic dementia. This is a critical step because some of these causes are fully treatable.
- Vitamin B12 levels: A deficiency can cause confusion, memory problems, and difficulty thinking clearly. Supplementation can reverse these symptoms.
- Thyroid function: Both an underactive and overactive thyroid can impair cognition. Thyroid-stimulating hormone (TSH) levels are checked as a standard part of the workup.
- Blood glucose: Uncontrolled diabetes can affect memory and thinking.
- Kidney and liver function: Organ dysfunction can cause a buildup of toxins that clouds thinking.
- Complete blood count: Infections and anemia can both contribute to cognitive symptoms.
- Toxicology screening: Drug interactions or substance use sometimes explain sudden cognitive changes, particularly in older adults taking multiple medications.
In some cases, doctors also test for infections known to affect the brain, such as HIV or syphilis, depending on the patient’s history. If any of these tests come back abnormal, treating the underlying condition may partially or fully resolve the cognitive symptoms.
A New Blood Test for Alzheimer’s Disease
A major recent development is an FDA-approved blood test that measures a specific protein ratio linked to Alzheimer’s disease. The test, approved for patients 55 and older who are already showing cognitive decline, looks at the ratio of a tau protein fragment to a type of amyloid protein in the blood.
Patients whose scores fall above the high-end cutoff have more than a 90% likelihood of having Alzheimer’s disease, while those below the low range almost certainly do not. About 20% of people tested fall into an intermediate zone that requires further evaluation with brain scans or spinal fluid analysis. The test is currently being rolled out through electronic medical record systems, with commercial labs in the process of acquiring the kits to run it. This is a significant shift because, until now, confirming Alzheimer’s-related brain changes required expensive PET scans or invasive spinal taps.
Brain Imaging
When screening and blood work suggest dementia, brain imaging helps identify what’s happening structurally and functionally inside the brain.
An MRI is the most common imaging study ordered. It shows the physical structure of the brain in detail, revealing patterns of shrinkage (atrophy) in specific regions. In Alzheimer’s disease, the hippocampus, which is the brain’s memory center, typically shrinks early. An MRI can also reveal evidence of strokes, tumors, fluid buildup, or other structural problems that cause or worsen cognitive symptoms.
A PET scan goes further by measuring brain activity rather than just structure. One type uses a radioactive glucose tracer to show which brain areas are metabolically active and which are not. In Alzheimer’s disease, areas with reduced glucose metabolism correspond to regions with significant neuron loss. Research comparing PET, MRI, and CT scans against autopsy findings has shown that PET imaging is a better measure of Alzheimer’s severity because it reflects the actual degree of neuron damage rather than just visible shrinkage. Another type of PET scan can detect amyloid plaques or tau protein tangles directly, providing strong evidence for or against Alzheimer’s as the cause.
Not everyone needs a PET scan. An MRI is often sufficient when combined with other test results, and PET scans are typically reserved for cases where the diagnosis remains uncertain.
Full Neuropsychological Evaluation
When the diagnosis is unclear or more detail is needed, a referral to a neuropsychologist provides the most comprehensive picture of cognitive function. This evaluation involves a battery of standardized tests covering memory, attention, processing speed, language, perceptual and motor skills, visual-spatial abilities, and executive functions like planning, organizing, and problem-solving.
The evaluation typically takes several hours, sometimes split across two sessions. The results create a detailed cognitive profile showing exactly which abilities are impaired and how severely. This matters for several reasons. It helps distinguish between dementia types, since Alzheimer’s disease tends to affect memory first while other forms may start with language or visual-spatial problems. It also establishes a baseline that can be compared against future testing to track whether symptoms are stable, improving, or getting worse. For people whose screening scores seem inconsistent with their daily functioning, this evaluation often provides the clearest answers.
Assessing Daily Functioning
A formal dementia diagnosis requires more than just poor test scores. It requires evidence that cognitive decline is interfering with your ability to function in daily life. Doctors assess this by looking at two categories of everyday tasks.
Basic activities of daily living are the physical essentials: bathing, grooming, dressing, feeding yourself, using the toilet, and moving around. Instrumental activities of daily living are more complex tasks that require planning and organization: managing money, cooking meals, doing laundry, keeping up with medications, shopping, and using the phone. Difficulty with instrumental tasks while basic tasks remain intact generally corresponds to a milder stage of dementia. When basic self-care becomes difficult, the condition has progressed further. When someone is fully dependent on others for all daily activities, this reflects the most severe stage.
Doctors often gather this information from both the patient and a close family member or caregiver, since people with cognitive decline frequently underestimate their difficulties. A structured questionnaire completed by someone who knows the patient well, rating changes across multiple everyday skills, can be as informative as a cognitive test in some cases.
Genetic Testing
Genetic testing plays a limited but sometimes useful role. The most well-known test looks for variants of the APOE gene. Carrying one or two copies of the APOE4 variant increases the risk of developing Alzheimer’s disease, but it is not a diagnosis. Many people with APOE4 never develop dementia, and many people without it do.
This test is voluntary and not part of routine dementia screening. You might consider it if you have a strong family history of Alzheimer’s and want to understand your personal risk. For people already diagnosed with Alzheimer’s, the test can sometimes help guide treatment decisions. It’s available through healthcare providers and also shows up on some direct-to-consumer genetic tests, though interpreting the results without medical context can cause unnecessary anxiety.
How the Pieces Come Together
No single test confirms dementia. A diagnosis is made by combining cognitive test results, blood work, imaging findings, functional assessments, and clinical judgment. The diagnostic criteria require evidence of significant cognitive decline in at least one domain (such as memory, language, or executive function) that represents a clear drop from a previous level of ability and that interferes with independence in everyday activities.
The full process, from initial screening to final diagnosis, can take weeks to months depending on how many tests are needed and how quickly specialist appointments are available. If your doctor suspects a straightforward case of Alzheimer’s with a clear history, typical imaging findings, and supporting blood work, the process may move quickly. Atypical cases, younger patients, or situations where multiple conditions overlap often require the full range of testing before a confident answer emerges.